Zimmer Biomet Holdings (ZBH) Updates on IDE Trial; Notes Improved AFS with cBMA Treatment

November 15, 2016 8:03 AM EST Send to a Friend
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced an update on its Investigational Device Exemption (IDE) clinical trial evaluating the use ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login